Benvenuto e introduzione 7° Riunione Nazionale di A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
Browsing: Acute Lymphoblastic Leukemia
SAN FRANCISCOThe ability of cancer cells to evolve clonally into molecularly distinct strands needs to be considered when selecting targeted…
NEW ORLEANSHigh remission rates with extended survival are being achieved in patients who had failed all other therapies including allogeneic…
LONDON Researchers have shown that endometrial cancer and hopefully ovarian cancer too could potentially be detected much earlier than at…
ORLANDO, FLORIDAPatients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from…
SAN FRANCISCONew research has shown the alpha-emitting drug radium 233 to be a benign therapy with no major toxicities while…
SAN FRANCISCO The orally administered androgen receptor blocker enzalutamide significantly extended both overall survival and radiographically determined progression-free survival in…
NEW ORLEANSA new oral tyrosine kinase inhibitor drug idelalisib has proved effective and to have low toxicity in patients with…
The rare, fatal lympho-proliferative condition: Multicentric Castleman’s Disease MCD could soon be treatable following findings announced at the American Society…
WASHINGTON DCA new type of immunotherapy has brought responses in children with acute lymphoblastic leukaemia in relapse who had no…
CAMBRIDGE, UKA new blood test promises quicker assessment of treatment efficacy in patients with metastatic breast cancer. Dr Dana Tsui…
ORLANDO, FLORIDAA decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients…
ORLANDO, FLORIDAPatients with low-risk prostate cancer are more likely to die with their disease than of it, according to Dr…
3-9-14 9:01am
3-9-14 8:50am
3-7-14 10:54 FLV
3-7-14 3:10pm
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Angela Dispenzieri discusses who should…